Table 2 FREEZE Cohort patients characteristics
Patient characteristics | CBA | RFA | P-value | OR (95% CI) |
|---|---|---|---|---|
Number of patients | 1560 (53.7%) | 1344 (46.3%) | ||
Age on admission [years] | 62.1 ± 10.6, N = 1560 | 63.2 ± 10.5, N = 1344 | 0.004 | |
Female | 37.1% (578/1559) | 36.2% (486/1342) | 0.63 | 1.04 (0.89–1.21) |
Weight [kg] | 83 (73, 95) | 85 (75, 96) | 0.067 | |
Paroxysmal AF | 68.8% (1073/1560) | 55.9% (751/1344) | < 0.001 | 1.74 (1.49–2.03) |
Persistent AF (lasting < 1 year) | 31.2% (487/1560) | 44.1% (593/1344) | < 0.001 | 0.57 (0.49–0.67) |
Frequency of episodes | ||||
Occasionally (less than once per months) | 12.2% (183/1503) | 5.4% (68/1262) | < 0.001 | 2.43 (1.82–3.25) |
Intermediate (once per month—almost daily) | 72.1% (1084/1503) | 80.3% (1014/1262) | < 0.001 | 0.63 (0.53–0.76) |
Frequent (at least daily) | 15.7% (236/1503) | 14.3% (180/1262) | 0.29 | 1.12 (0.91–1.38) |
EHRA symptom score III/IV | 57.0% (889/1559) | 78.3% (1049/1340) | < 0.001 | 0.37 (0.31–0.43) |
Previous non-AF ablation | 9.2% (144/1560) | 10.1% (136/1344) | 0.42 | 0.90 (0.71–1.16) |
Previous device implant* | 3.8% (60/1560) | 8.0% (107/1344) | < 0.001 | 0.46 (0.33–0.64) |
Number of cadioversions/defibrillation | 1.0 ± 1.5, N = 1356 | 1.2 ± 1.4, N = 901 | < 0.001 | |
Structural heart disease | 45.1% (704/1560) | 43.3% (580/1341) | 0.31 | 1.08 (0.93–1.25) |
Coronary heart disease | 10.7% (167/1560) | 13.4% (180/1340) | 0.024 | 0.77 (0.62–0.97) |
History of myocardial infarction | 1.9% (29/1560) | 3.6% (48/1340) | 0.004 | 0.51 (0.32–0.81) |
Vitium | 6.0% (94/1560) | 17.6% (236/1340) | < 0.001 | 0.30 (0.23–0.39) |
Aortic valve | 1.9% (30/1555) | 4.3% (58/1340) | < 0.001 | 0.43 (0.28–0.68) |
Mitral valve | 3.5% (55/1555) | 11.0% (148/1340) | < 0.001 | 0.30 (0.21–0.41) |
Cardiomyopathy | 3.8% (59/1560) | 4.3% (57/1340) | 0.52 | 0.88 (0.61–1.28) |
Hypertensive heart disease | 31.0% (483/1560) | 17.2% (231/1340) | < 0.001 | 2.15 (1.80–2.57) |
Primary electrical heart disease | 0.8% (12/1560) | 2.8% (37/1340) | < 0.001 | 0.27 (0.14–0.53) |
Other leading heart disease | 4.4% (63/1428) | 2.6% (35/1324) | 0.012 | 1.70 (1.12–2.59) |
Heart failure | 0.9% (14/1560) | 2.5% (33/1343) | < 0.001 | 0.36 (0.19–0.67) |
NYHA functional class III/IV | 3.4% (49/1434) | 18.3% (195/1068) | < 0.001 | 0.16 (0.11–0.22) |
Cardiac imaging | ||||
LVEF [%] | 60 (55, 60) | 55 (55, 60) | < 0.001 | |
Left atrial diameter [mm] | 42 (39, 47) | 42 (39, 48) | 0.027 | |
Concomitant diseases | 70.8% (1105/1560) | 78.2% (1050/1343) | < 0.001 | 0.68 (0.57–0.80) |
Hypertension | 64.0% (999/1560) | 68.1% (914/1343) | 0.023 | 0.84 (0.72–0.98) |
Diabetes | 6.6% (103/1560) | 9.6% (129/1343) | 0.003 | 0.67 (0.51–0.87) |
Renal failure (GFR < 60) | 4.0% (62/1560) | 5.3% (71/1343) | 0.092 | 0.74 (0.52–1.05) |
S-Creatinine [mg/dl] | 0.9 (0.8, 1.0) | 0.9 (0.8, 1.1) | < 0.001 | |
COPD | 2.0% (31/1560) | 5.0% (67/1343) | < 0.001 | 0.39 (0.25–0.59) |
Rheumatoid disease | 1.0% (16/1560) | 2.5% (33/1343) | 0.003 | 0.41 (0.23–0.75) |
CHA2DS2-Vasc Score | 1.9 ± 1.3, N = 1559 | 2.1 ± 1.4, N = 1337 | < 0.001 | |
Current rhythm | ||||
Sinus rhythm | 86.1% (1343/1560) | 66.9% (894/1337) | < 0.001 | 3.07 (2.55–3.68) |
Atrial fibrillation | 12.3% (192/1560) | 31.4% (420/1337) | < 0.001 | 0.31 (0.25–0.37) |
PM | 1.5% (23/1560) | 1.0% (14/1337) | 0.31 | 1.41 (0.72–2.76) |
Other | 0.5% (8/1560) | 0.9% (12/1337) | 0.21 | 0.57 (0.23–1.40) |